

Field Name	Field Description
Prior Authorization Group Description	Dendritic Cell Tumor Peptide Immunotherapy
Drugs	Provenge (sipuleucel-T)
Covered Uses	Medically accepted indications are defined using the following sources: the Food and Drug Administration (FDA), Micromedex, American Hospital Formulary Service (AHFS), United States Pharmacopeia Drug Information for the Healthcare Professional (USP DI), the Drug Package Insert (PPI), or disease state specific standard of care guidelines.
Exclusion Criteria	Small cell/neuroendocrine prostate cancer
Required Medical Information	See “Other Criteria”
Age Restrictions	See “Other Criteria”
Prescriber Restrictions	Prescriber must be an oncologist or urologist
Coverage Duration	If all the criteria are met, the request will be approved for 3 doses per lifetime
Other Criteria	<u>Initial Authorization:</u> - Metastatic castrate resistant (hormone-refractory) prostate cancer (mCRPC) (consistent with medical chart history) - Evidenced by soft tissue and/or bony metastases - Patient does NOT have - M0CRPC (defined as CRPC whose only evidence of disseminated disease is an elevated serum PSA) is not authorized - Visceral metastases (e.g. liver, lung, adrenal, peritoneal, brain) - Patient is not currently being treated with systemic immunosuppressants (e.g. chemotherapy, corticosteroids) or, if the patient is being treated with immunosuppressants, the prescriber has provided a valid medical reason for combination therapy - Eastern Cooperative Oncology Group (ECOG) score 0-1 - Serum testosterone <50 ng/dL (e.g. castration levels of testosterone) - Predicted survival of at least six months <u>Reauthorization:</u> - Treatment exceeding 3 doses per lifetime will not be authorized Medical Director/clinical reviewer must override criteria when, in his/her professional judgement, the requested item is medically necessary.
Revision/Review Date 4/2025	